Treprostinil
Brand name: Tyvaso Dpi
Rank #112 of 500 drugs by total cost
$158.9M
Total Cost
6,704
Total Claims
$158.9M
Total Cost
187
Prescribers
$24K
Cost per Claim
354
Beneficiaries
6,711
30-Day Fills
$850K
Avg Cost/Provider
36
Avg Claims/Provider
About Treprostinil
Treprostinil (sold as Tyvaso Dpi) was prescribed 6,704 times by 187 Medicare Part D providers in 2023, costing the program $158.9M. At $24K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 109 | Alirocumab (Praluent Pen) | $165.6M | 203,805 |
| 110 | Pantoprazole Sodium (Pantoprazole Sodium) | $165.1M | 10,061,854 |
| 111 | Lenvatinib Mesylate (Lenvima) | $164.6M | 7,004 |
| 112 | Treprostinil (Tyvaso Dpi) | $158.9M | 6,704 |
| 113 | Rimegepant Sulfate (Nurtec Odt) | $155.0M | 106,692 |
| 114 | Teriparatide (Forteo) | $153.9M | 38,259 |
| 115 | Ixekizumab (Taltz Autoinjector) | $149.8M | 19,972 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology